Human papilloma virus (HPV) vaccine and cervical cancer prevention in Africa
Abstract
References
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, LaubySecretan B, Arbyn M, Basu P, Bray F and Vaccarella S.
Global estimates of incidence and mortality of cervical
cancer in 2020: a baseline analysis of the WHO Global
Cervical Cancer Elimination Initiative. The Lancet Global
Health. 2023 Feb 1;11(2):e197-206.
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto
J, Schiffman MH, Moreno V, Kurman R and Shah KV.
Prevalence of human papillomavirus in cervical cancer: a
worldwide perspective. Obstetrical & Gynecological
Survey. 1995 Oct 1;50(10):725-7.
Ahmed HG, Bensumaidea SH, Alshammari FD, Alenazi FSH,
ALmutlaq BA, Alturkstani MZ and Aladani IA. Prevalence
of Human Papillomavirus subtypes 16 and 18 among
Yemeni Patients with Cervical Cancer. Asian Pac J Cancer
Prev. 2017 Jun 25;18(6):1543-1548. doi:
22034/APJCP.2017.18.6.1543. PMID: 28669165;
PMCID: PMC6373819.
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS
and Brotherton JM. Human papillomavirus vaccine introduction–the first five years. Vaccine. 2012 Nov
;30:F139-48.
African renewal. Nigeria to vaccinate 7.7million against the
leading cause of cervical cancer. Retrieved from: Nigeria
to vaccinate 7.7 million girls against leading cause of
cervical cancer | Africa Renewal (un.org)
Pollack AE, Balkin M, Edouard L, Cutts F and Broutet N. Ensuring
access to HPV vaccines through integrated services: a
reproductive health perspective. Bulletin of the World
Health Organization. 2007 Jan;85(1):57-63.
Refbacks
- There are currently no refbacks.






